See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a drug that has been tested in combination with other medications for various types of cancers. According to the information provided, one study tested lurbinectedin in combination with doxorubicin for the treatment of small cell lung cancer (SCLC) [1]. Another study examined the use of lurbinectedin in combination with irinotecan for the treatment of relapsed SCLC [2].

It is important to note that the information provided does not specify if lurbinectedin has been tested in combination with any other drugs beyond those mentioned above. However, DrugPatentWatch.com, a comprehensive database of pharmaceutical and biotechnology patents, lists several other drugs that have been studied in combination with lurbinectedin, including but not limited to: topotecan, gemcitabine, and paclitaxel [3]. These combinations have been investigated for the treatment of various types of cancer, including ovarian, lung, and breast cancer.

In summary, lurbinectedin has been tested in combination with doxorubicin and irinotecan for the treatment of small cell lung cancer. Additionally, DrugPatentWatch.com lists several other drugs that have been studied in combination with lurbinectedin for the treatment of various types of cancer.

Sources:

[1] ClinicalTrials.gov. (2021). A Study of Lurbinectedin in Combination With Doxorubicin in Participants With Small Cell Lung Cancer. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT02566993>

[2] ClinicalTrials.gov. (2021). A Study of Lurbinectedin in Combination With Irinotecan in Participants With Small Cell Lung Cancer. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT02454972>

[3] DrugPatentWatch.com. (2021). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>